Prescient Therapeutics has extended its Share Purchase Plan by three days after shareholders reported delays receiving application documents. The revised timetable places the offer’s results announcement just ahead of a planned briefing on the company’s PTX-100 development program.
- SPP closing date moved to 18 September 2026
- Shares priced at $0.065, an 18.8% VWAP discount
- Eligible shareholders can apply for up to A$30,000
- SPP results due on 24 September
- CEO James McDonnell to discuss the PTX-100 Dose Optimisation Committee review
Three-Day Extension for Shareholders
Prescient Therapeutics (ASX:PTX) has given eligible shareholders three extra days to participate in its Share Purchase Plan, moving the closing date from 15 September to 5.00pm on 18 September 2026. The company said the extension followed requests from shareholders who experienced delays receiving the SPP documentation.
The offer remains priced at $0.065 a share, representing an 18.8% discount to the volume-weighted average price over the 10 trading days before the SPP was announced. Eligible holders registered at 7.00pm on 24 August can apply for up to A$30,000 of new ordinary shares.
Participation Encourages Board
Prescient said it was encouraged by shareholder participation to date and noted that all eligible directors had taken part. The announcement does not disclose the amount raised so far, the offer’s target proceeds or the level of demand against the available allocation, leaving the scale of the capital raising unresolved until the results are released.
The revised timetable sets the SPP results announcement for 24 September, with the new shares expected to be issued on 25 September and trading, subject to ASX listing rules, scheduled for 28 September. Those dates matter more than the administrative extension itself: they are when shareholders will learn whether the plan has produced the funding base Prescient is seeking.
PTX-100 Briefing Adds a Clinical Catalyst
The SPP deadline now coincides with an online investor briefing led by chief executive James McDonnell, who is due to discuss the Dose Optimisation Committee review milestone for PTX-100. Prescient described that review as a significant step towards advancing the targeted cancer therapy into its next stage of development, but the announcement does not provide new clinical results or a committee decision.
Prescient’s existing disclosure describes PTX-100 as a GGTase-1 inhibitor being developed for cancer indications including T-cell lymphomas. The company says a global Phase 2 study in cutaneous T-cell lymphoma is recruiting, while the broader platform portfolio remains at varying stages of development. The immediate test for investors is therefore twofold: how much capital the SPP ultimately secures, and what substantive information emerges from the PTX-100 review milestone.
Bottom Line?
The extension buys shareholders time, but it also postpones clarity on the capital raised; the 24 September SPP result and PTX-100 briefing are the next material markers.
Questions in the middle?
- How much will the SPP raise when results are released on 24 September?
- What decision or next-stage plan will emerge from the PTX-100 Dose Optimisation Committee review?
- Will the company provide updated funding guidance once the SPP proceeds and share count are known?